Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $7.10 USD
Change Today +0.15 / 2.16%
Volume 4.2K
ARDM On Other Exchanges
As of 8:10 PM 10/8/15 All times are local (Market data is delayed by at least 15 minutes).

aradigm corp (ARDM) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/21/14 - $8.93
52 Week Low
03/27/15 - $6.17
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ARADIGM CORP (ARDM)

Related News

No related news articles were found.

aradigm corp (ARDM) Related Businessweek News

No Related Businessweek News Found

aradigm corp (ARDM) Details

Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases. Its lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with severe respiratory diseases, such as non-cystic fibrosis bronchiectasis (BE) and cystic fibrosis (CF). The company is conducting Phase 3 clinical trials with Pulmaquin in BE; Phase 2b trial with Lipoquin and Pulmaquin in BE. It has also completed a Phase 2a trial with Lipoquin in CF and Phase 2a trial with Lipoquin in BE. The company’s proprietary program under development comprises ARD-1600 Inhaled Nicotine, a smoking cessation therapy. The company has collaboration agreements with Oregon State University and Grifols, S.A. Aradigm Corporation was founded in 1991 and is headquartered in Hayward, California.

18 Employees
Last Reported Date: 03/18/15
Founded in 1991

aradigm corp (ARDM) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $400.0K
Chief Financial Officer, Vice President of Fi...
Total Annual Compensation: $305.0K
Chief Medical Officer
Total Annual Compensation: $365.0K
Compensation as of Fiscal Year 2014.

aradigm corp (ARDM) Key Developments

Aradigm Corporation Completes Enrollment in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-4)

Aradigm Corporation announced the completion of enrollment in the ORBIT-4 Phase III pivotal clinical trial of Pulmaquin®, Aradigm’s proprietary investigational formulation of inhaled ciprofloxacin, for the treatment of patients with non-cystic fibrosis bronchiectasis (non-CF BE) who have chronic lung infections with Pseudomonas aeruginosa. ORBIT-4 is one of two Phase III pivotal clinical trials Aradigm is conducting with Pulmaquin in this patient population with an unmet medical need. The worldwide, double-blind, placebo-controlled pivotal trial enrolled 304 patients across 16 countries, including the U.S., Canada, Australia, New Zealand, Israel, South Korea, Peru and countries in Europe. The Phase III clinical program for Pulmaquin in BE consists of two worldwide, double-blind, placebo-controlled pivotal trials (ORBIT-3 and ORBIT-4) that are identical in design except for a pharmacokinetics sub-study to be conducted in one of the trials. The dosing regimen for each trial consists of a 48 week double blind period of 6 cycles of 28 days on treatment/28 days off treatment with Pulmaquin or placebo, followed by a 28 day open label extension in which all participants will receive Pulmaquin. The superiority of Pulmaquin vs. placebo during the double blind period will be evaluated in terms of the time to first pulmonary exacerbation (primary endpoint), while key secondary endpoints include the reduction in the number of pulmonary exacerbations, including severe episodes, and improvements in specific quality of life measures. Lung function is being monitored as a safety indicator. Bronchiectasis is a severe, chronic and rare disease characterized by bronchial wall damage diagnosed as abnormal dilatation of the bronchi and bronchioles, frequently associated with chronic lung infections and a vicious cycle of inflammation and episodes of acute worsening. In these severely affected adult patients, infections with Pseudomonas aeruginosa are associated with an approximately 3-fold increased risk of death and an increase in hospital admissions and exacerbations. Non-CF BE represents an unmet medical need that affects more than 110,000 people in the U.S. and over 200,000 people in Europe There is currently no drug approved for the treatment of this condition to prevent pulmonary exacerbations.

Aradigm Corp Amends Bylaws

On September 1, 2015, following the resignation of Mr. Lafmin Morgan from the Board, the Board approved an amendment to the Aradigm Corporation's Bylaws reducing the size of the Board from six to five directors, effective immediately.

Aradigm Corp Announces Board Changes

On September 1, 2015, the Board of Aradigm Corp. accepted the resignation of Lafmin Morgan, who offered his resignation as a director of the company due to increased professional responsibilities required at his current position at Grifols. The Board, Grifols and Mr. Morgan agreed to enter into a Board Observer Agreement to allow Mr. Morgan to continue as a representative of Grifols as a non-voting observer in future meetings of the Board. The Board Observer Agreement provides that Grifols may designate a Board observer in lieu of designating a nominee to the Board as provided under the Governance Agreement. Following the acceptance of Mr. Morgan's resignation, the Board reduced the size of the Board from six directors to five directors. The Board also appointed director Fred Hudson to fill the vacancy on the Compensation Committee that was created by Mr. Morgan's resignation from the Board.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARDM:US $7.10 USD +0.15

ARDM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alexza Pharmaceuticals Inc $1.26 USD 0.00
Alkermes PLC $59.90 USD -0.08
Bayer AG €110.85 EUR -2.45
Gilead Sciences Inc $100.81 USD +0.54
GlaxoSmithKline PLC 1,308 GBp +16.00
View Industry Companies

Industry Analysis


Industry Average

Valuation ARDM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.1x
Price/Book 2.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARADIGM CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at